Related Experiment Video
Updated: May 13, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical
Michal J Besser1, Tsipi Shoham, Orit Harari-Steinberg
1Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel.
Abstract:
Natural killer (NK) cells have long been considered as potential agents for adoptive cell therapy for solid cancer patients. Until today most studies utilized autologous NK cells and yielded disappointing results. Here we analyze various modular strategies to employ allogeneic NK cells for adoptive cell transfer, including donor-recipient HLA-C mismatching, selective activation and induction of melanoma-recognizing lysis receptors, and co-administration of antibodies to elicit antibody-dependent cell cytotoxicity (ADCC). We show that NK cell activation and induction of the relevant lysis receptors, as well as co-administration of antibodies yield substantial anti-cancer effects, which are functionally superior to HLA-C mismatching. Combination of the various strategies yielded improved effects. In addition, we developed various clinically-compatible ex vivo expansion protocols that were optimized according to fold expansion, purity and expression of lysis receptors. The main advantages of employing allogeneic NK cells are accessibility, the ability to use a single donor for many patients, combination with various strategies associated with the mechanism of action, e.g. antibodies and specific activation, as well as donor selection according to HLA or CD16 genotypes. This study rationalizes a clinical trial that combines adoptive transfer of highly potent allogeneic NK cells and antibody therapy.
Insights
Allogeneic natural killer (NK) cells show promise for adoptive cell therapy in solid cancers. Combining NK cell activation, antibody therapy, and optimized expansion protocols enhances anti-cancer effects.
Area of Science:
- Immunology
- Cancer Therapy
- Cellular Biology
Background:
- Natural killer (NK) cells are explored for adoptive cell therapy in solid tumors.
- Previous studies using autologous NK cells have shown limited success.
- Allogeneic NK cells offer potential advantages for broader application.
Purpose of the Study:
- To investigate modular strategies for enhancing allogeneic NK cell therapy.
- To evaluate the efficacy of HLA-C mismatching, receptor induction, and antibody co-administration.
- To develop clinically compatible ex vivo expansion protocols for NK cells.
Main Methods:
- Analysis of donor-recipient HLA-C mismatching.
- Selective activation and induction of melanoma-recognizing lysis receptors.
- Co-administration of antibodies for antibody-dependent cell cytotoxicity (ADCC).
- Development and optimization of ex vivo NK cell expansion protocols.
Main Results:
- NK cell activation and receptor induction, along with antibody co-administration, produced significant anti-cancer effects.
- These strategies were functionally superior to HLA-C mismatching alone.
- Combined strategies demonstrated improved anti-cancer efficacy.
- Optimized expansion protocols yielded high purity and receptor expression.
Conclusions:
- Allogeneic NK cells are accessible and can be used for multiple patients.
- Combining strategies like antibody therapy and specific activation enhances NK cell potency.
- Donor selection based on HLA or CD16 genotypes can further optimize therapy.
- The findings support a clinical trial combining allogeneic NK cell transfer with antibody therapy.
